Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02IHW
|
|||
| Former ID |
DIB003293
|
|||
| Drug Name |
Nepafenac
|
|||
| Synonyms |
Nevanac; AHR-9434; AL-6515
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Osteoarthritis [ICD-11: FA00-FA05; ICD-9: 715] | Approved | [1], [2], [3] | |
| Company |
Alcon
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H14N2O2
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)C(=O)C2=CC=CC(=C2N)CC(=O)N
|
|||
| InChI |
1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18)
|
|||
| InChIKey |
QEFAQIPZVLVERP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 78281-72-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10251001, 14774447, 46227657, 47206867, 49835179, 50070143, 50070890, 50331436, 57347256, 71883489, 85175724, 91749960, 92723396, 99437054, 99443294, 103274041, 104430113, 109693308, 117525219, 118046492, 118314630, 124757120, 124772072, 124896627, 125163924, 125357725, 126617535, 126649074, 126667064, 126731914, 129010085, 135107093, 136949089, 137239515, 137322723, 143496452, 144206538, 152239385, 152258756, 160647601, 160871507, 160967911, 162011723, 162201751, 164175283, 164347474, 164788880, 165235518, 170465203, 172914302
|
|||
| ChEBI ID |
CHEBI:75922
|
|||
| ADReCS Drug ID | BADD_D01555 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin G/H synthase (COX) | Target Info | Inhibitor | [3], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7564). | |||
| REF 2 | 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):409-15. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.